Preprint / Version 1

Analysis of COVID-19 and Inflammatory Bowel Disease: An in-depth literature review

Authors

  • Rupalakshmi Vijayan Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Shavy Nagpal Division of Research, Larkin Community Hospital, South Miami, Florida, US https://orcid.org/0000-0002-4327-1711
  • Isha Mehta Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Kazi Anwar Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Charmy Parikh Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Osama Faleh Odeh Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Charitha Koneru Division of Research, Larkin Community Hospital, South Miami, Florida, US
  • Siva Keerthana Suddapalli Division of Research, Larkin Community Hospital, South Miami, Florida, US

DOI:

https://doi.org/10.21467/preprints.351

Abstract

Introduction: The world is experiencing some of the most complex consequences of the pandemic, with an accelerated growth of cases and deaths and a huge burden for the health systems, especially in immunocompromised individuals. In the healthcare system, the extent of impact of COVID-19 in patients with chronic diseases like inflammatory bowel disease (IBD) need its scientific attention.

Methods: An extensive literature search was done using ‘COVID – 19’, ‘SARS-CoV-2’, ‘IBD’ using google scholar, clinical trials.gov, and PubMed indexed journals.

Results: SARS-CoV-2 has been isolated in the duodenum and rectum, and a higher concentration of fecal calprotectin, a known inflammatory marker, has been found in infected patients with diarrhea compared with those without diarrhea (123.2 vs 17.3 ?g/g; P < .001), suggesting that viral gut tropism could worsen inflammatory status and symptoms of IBD patient. In gist, symptoms experienced by IBD patients with COVID-19 are similar to those occurring in the general population, except for a higher percentage of diarrhea.

Conclusions: The aim of our study is to compare the incidence and clinical outcomes of COVID-19 in patients with IBD to the general population by using literature review. With increased risk of acquisition of COVID-19 in IBD patients, these patients can be asymptomatic or can present with typical symptoms of sore throat, fever, cough, dyspnea, sputum production, myalgia, fatigue, and headache.

Downloads

Download data is not yet available.

References

- Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.), 367(6485), 1444–1448. https://doi.org/10.1126/science.abb2762

Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020). Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, 158(6), 1831–1833.e3. https://doi.org/10.1053/j.gastro.2020.02.055

- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052

- Deepak, P., Stobaugh, D. J., & Ehrenpreis, E. D. (2013). Infectious complications of TNF-? inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. Journal of gastrointestinal and liver diseases : JGLD, 22(3), 269–276.

- Brenner, E. J., Ungaro, R. C., Gearry, R. B., Kaplan, G. G., Kissous-Hunt, M., Lewis, J. D., Ng, S. C., Rahier, J. F., Reinisch, W., Ruemmele, F. M., Steinwurz, F., Underwood, F. E., Zhang, X., Colombel, J. F., & Kappelman, M. D. (2020). Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology, 159(2), 481–491.e3. https://doi.org/10.1053/j.gastro.2020.05.032

- Norsa, L., Indriolo, A., Sansotta, N., Cosimo, P., Greco, S., & D'Antiga, L. (2020). Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy. Gastroenterology, 159(1), 371–372. https://doi.org/10.1053/j.gastro.2020.03.062

- An P, Ji M, Ren H, et al. Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China. SSRN. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3543590. Published February 27, 2020. Accessed April 22, 2021.

- Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Xu, L., … Song, Y. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine, 180(7), 934–943. https://doi.org/10.1001/jamainternmed.2020.0994

- Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K., Wu, A., Chiu, R. W., Wong, V. W., Chan, P. K., Wong, K. T., Wong, E., Cockram, C. S., Tam, J. S., Sung, J. J., & Lo, Y. M. (2004). Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 31(4), 304–309. https://doi.org/10.1016/j.jcv.2004.07.006

Attauabi, M., Seidelin, J. B., Felding, O. K., Wewer, M. D., Vinther Arp, L. K., Sarikaya, M. Z., Egeberg, A., Vladimirova, N., Bendtsen, F., & Burisch, J. (2021). Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study. Journal of autoimmunity, 118, 102613. https://doi.org/10.1016/j.jaut.2021.102613

- Beaugerie, L., & Kirchgesner, J. (2019). Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(3), 370–379. https://doi.org/10.1016/j.cgh.2018.07.013

Anikhindi SA, Kumar A, Arora A. COVID-19 in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2020 Dec;14(12): 1187-1193.

Taxonera C, Sagastagoitia I, Alba C, et al. 2019 Novel Coronavirus Disease (COVID?19) in patients with Inflammatory bowel diseases. Aliment Pharmacol Ther [Internet]. 2020 [cited 2020 Aug 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267496/

Downloads

Posted

2021-11-26

Section

Coronavirus

Categories

License

Copyright (c) 2021 Rupalakshmi Vijayan , Shavy Nagpal, Isha Mehta, Kazi Anwar, Charmy Parikh, Osama Faleh Odeh, Charitha Koneru, Siva Keerthana Suddapalli

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.